BioMarin Pharmaceutical Plans To Discontinue Dosing, Enrollment In Its Phase 2 Studies For VOXZOGO In Turner Syndrome

Benzinga Newsdesk www.benzinga.com Neutral 92.3%

Neg 0% Neu 92.3% Pos 0%

SEC.

Comments

No comments yet. Be the first!